AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 336.04B |
| Revenue (ttm) | 49.67B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 106.00 |
| Forward PE | 16.99 |
| Dividend | 5.86 (3.13%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | n/a |
| Average Volume | 364 |
| Open | 189.80 |
| Previous Close | 189.20 |
| Day's Range | 189.80 - 189.80 |
| 52-Week Range | 147.00 - 203.05 |
| Beta | n/a |
| RSI | 62.49 |
| Earnings Date | Oct 29, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
SKINVIVE ® to launch in 35 additional markets worldwide from September taking the total to 57 international launches in 2025. Research highlights 94% of people want to improve facial skin quality1*, w...
These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech
DataTrek remains positive on U.S. large cap stocks, but expects more bearish commentary related to valuation in the days ahead
Analyst Evercore ISI Group Raises Price Target for AbbVie (ABBV) to $222 | ABBV Stock News
Analyst Evercore ISI Group Raises Price Target for AbbVie (ABBV) to $222 | ABBV Stock News
Validea Detailed Fundamental Analysis - ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim v...
The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh
Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.
Top Analyst Reports for AbbVie, ServiceNow & Boeing
AbbVie, ServiceNow, and Boeing outpace their industries as analysts highlight growth drivers and risks in fresh research reports.
Noteworthy Thursday Option Activity: ZS, CRM, ABBV
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zscaler Inc (Symbol: ZS), where a total of 10,858 contracts have traded so far, representin...
Notable ETF Inflow Detected - ITOT, HD, ABBV, AMD
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we h...
How Do Investors Really Feel About AbbVie?
AbbVie's (NYSE: ABBV) short interest as a percent of float has fallen 9.38% since its last report. According to exchange reported data, there are now 15.40 million shares sold short , which is 0.87% ...
Calls of the Day: Netflix, Disney, Walmart and AbbVie
The Investment Committee debate the latest Calls of the Day.
Calls of the Day: Netflix, Disney, Walmart and AbbVie
The Investment Committee debate the latest Calls of the Day.
SA analyst upgrades/downgrades: AMD, SNOW, MU, and ABBV
Explore the latest stock upgrades and downgrades on Snowflake, AMD, Micron, and AbbVie, plus analyst strategies.
Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker
Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.
Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial
This Workday Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
ABBV Gains Analyst Upgrade and Price Target Boost to $270 | ABBV Stock News
ABBV Gains Analyst Upgrade and Price Target Boost to $270 | ABBV Stock News
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
AbbVie Inc. is downgraded to sell amid valuation risks, low dividend yield, rising debt, and policy uncertainties. Click for our ABBV stock update.
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
AbbVie surges 22.5% YTD as new drugs Skyrizi and Rinvoq drive growth, offsetting Humira losses and fueling long-term momentum.
ABBV Quantitative Stock Analysis
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha ...
ABBV Updated with Overweight Rating and Adjusted Price Target by JP Morgan | ABBV Stock News
ABBV Updated with Overweight Rating and Adjusted Price Target by JP Morgan | ABBV Stock News
AbbVie's VRAYLAR® Gains Public Reimbursement In Alberta For Schizophrenia Treatment
(RTTNews) - AbbVie (ABBV) announced that Alberta has added VRAYLAR® - cariprazine to its Health Drug Formulary, expanding public coverage for adults living with schizophrenia.
AbbVie (ABBV) Sees Raised Price Target with Overweight Rating | ABBV Stock News
AbbVie (ABBV) Sees Raised Price Target with Overweight Rating | ABBV Stock News
Guru Fundamental Report for ABBV
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha ...
AbbVie (ABBV) Shares Cross 3% Yield Mark
Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 3% mark based on its quarterly dividend (annualized to...